NovaBay Accounts Payable vs Current Deferred Revenue Analysis
NBY Stock | USD 3.44 0.21 5.75% |
NovaBay Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NovaBay Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NovaBay Pharmaceuticals is a good investment. Please check the relationship between NovaBay Pharmaceuticals Accounts Payable and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.
Accounts Payable vs Current Deferred Revenue
Accounts Payable vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NovaBay Pharmaceuticals Accounts Payable account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between NovaBay Pharmaceuticals' Accounts Payable and Current Deferred Revenue is -0.65. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of NovaBay Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NovaBay Pharmaceuticals' Accounts Payable and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of NovaBay Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Accounts Payable i.e., NovaBay Pharmaceuticals' Accounts Payable and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.65 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents NovaBay Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NovaBay Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from NovaBay Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Selling General Administrative is likely to rise to about 7.5 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6M | 7.8M | 7.9M | 8.1M | Total Revenue | 8.4M | 14.4M | 14.7M | 10.0M |
NovaBay Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
NovaBay Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NovaBay Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
Total Stockholder Equity | 973K | 12.3M | 10.2M | 10.6M | 3.3M | 5.3M | |
Other Assets | 477K | 912K | 476K | 489K | 562.4K | 461.6K | |
Common Stock Shares Outstanding | 618.3K | 1.0M | 1.2M | 1.6M | 4.2M | 4.4M | |
Liabilities And Stockholders Equity | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
Other Stockholder Equity | 125.7M | 148.0M | 150.9M | 165.1M | 176.4M | 185.2M | |
Total Liab | 10.2M | 2.9M | 13.8M | 5.8M | 5.7M | 7.1M | |
Other Current Liab | 993K | 1.4M | 803K | 917K | 570K | 541.5K | |
Total Current Liabilities | 5.7M | 2.8M | 3.4M | 4.3M | 4.3M | 4.1M | |
Property Plant And Equipment Net | 1.4M | 520K | 604K | 2.0M | 1.4M | 1.0M | |
Net Debt | (2.9M) | (11.4M) | (7.0M) | (3.3M) | (390K) | (409.5K) | |
Retained Earnings | (125.0M) | (136.1M) | (141.9M) | (158.2M) | (174.8M) | (166.1M) | |
Accounts Payable | 331K | 302K | 1.0M | 1.1M | 1.1M | 812.7K | |
Cash | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 6.0M | |
Non Current Assets Total | 1.8M | 996K | 10.8M | 5.1M | 1.9M | 2.0M | |
Cash And Short Term Investments | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 3.0M | |
Common Stock Total Equity | 154K | 171K | 279K | 418K | 480.7K | 263.6K | |
Other Current Assets | 105K | 102K | 144K | 113K | 388K | 271.6K | |
Property Plant And Equipment Gross | 1.4M | 520K | 1.2M | 2.6M | 2.1M | 1.1M | |
Total Current Assets | 9.4M | 14.2M | 13.2M | 11.3M | 7.2M | 9.5M | |
Accumulated Other Comprehensive Income | (243K) | (509K) | (560K) | (275K) | (247.5K) | (259.9K) | |
Common Stock | 279K | 418K | 478K | 652K | 112K | 106.4K | |
Property Plant Equipment | 110K | 520K | 604K | 2.0M | 1.8M | 1.8M | |
Other Liab | 2.5M | 560K | 4.1M | 10.1M | 11.6M | 12.2M | |
Current Deferred Revenue | 822K | 730K | 1.3M | 1.8M | 946K | 1.2M | |
Non Current Liabilities Total | 4.6M | 87K | 10.4M | 1.6M | 1.4M | 2.6M | |
Short Term Debt | 3.5M | 416K | 305K | 453K | 1.6M | 1.7M | |
Non Currrent Assets Other | 77K | 2K | 476K | 489K | 21K | 20.0K | |
Net Receivables | 1.1M | 1.1M | 1.7M | 2.0M | 759K | 721.1K | |
Net Tangible Assets | 5.0M | 973K | 12.3M | (237K) | (213.3K) | (202.6K) | |
Retained Earnings Total Equity | (111.1M) | (115.0M) | (125.0M) | (136.1M) | (122.5M) | (116.3M) | |
Capital Surpluse | 125.7M | 148.0M | 150.9M | 165.1M | 189.8M | 118.8M | |
Inventory | 492K | 608K | 3.2M | 3.4M | 2.9M | 3.0M | |
Non Current Liabilities Other | 198K | 4.6M | 561K | 334K | 300.6K | 285.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NovaBay Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NovaBay Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novabay Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novabay Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for NovaBay Stock analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (120.40) | Revenue Per Share 1.521 | Quarterly Revenue Growth (0.16) | Return On Assets (0.32) | Return On Equity (2.52) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.